Who is most at risk for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the US?

Who is most at risk for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the US?

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Chronic Fatigue Syndrome (CFS), derived from prevalence insights from the CDC between 2021-2022, is a health concern that cuts across various demographic lines in the US. 

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE